Dr. STEFANY CARDOSO FARIA - MÉDICO ONCOLOGISTA

NICE Approves Nivolumab/Ipilimumab Combo for Melanoma Silas Inman @silasinman Published Online: Monday, Jun 20, 2016 James Larkin, MD, PhD James Larkin, MD, PhD The National Institute for Health and Care Excellence (NICE) has approved the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) for patients with metastatic melanoma, which allows the combination to be used within the National Health Service (NHS). The decision arrived just 2 months following a positive recommendation from the Committee for Medicinal Products for Human Use (CHMP) and 1 month following an approval from the European Commission. The decision was based upon a collection of data from the CheckMate-067 and -069 studies. In the phase III CheckMate-067 and the CheckMate-069 trials, the combination significantly improved objective response rates (ORR) and progression-free survival (PFS) versus monotherapy with ipilimumab for patients with advanced melanoma. In CheckMate-067, the combination demonstrated a

NICE Approves Nivolumab/Ipilimumab Combo for Melanoma Silas Inman @silasinman Published Online: Monday, Jun 20, 2016 James Larkin, MD, PhD James Larkin, MD, PhD The National Institute for Health and Care Excellence (NICE) has approved the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) for patients with metastatic melanoma, which allows the combination to be used within the National Health Service (NHS). The decision arrived just 2 months following a positive recommendation from the Committee for Medicinal Products for Human Use (CHMP) and 1 month following an approval from the European Commission. The decision was based upon a collection of data from the CheckMate-067 and -069 studies. In the phase III CheckMate-067 and the CheckMate-069 trials, the combination significantly improved objective response rates (ORR) and progression-free survival (PFS) versus monotherapy with ipilimumab for patients with advanced melanoma. In CheckMate-067, the combination demonstrated a